AbbVie is acquiring Apogee Therapeutics in a deal worth approximately $10.9 billion. The acquisition is reportedly focused on long-acting autoimmune drugs, which may include treatments for conditions such as eczema. The deal is considered one of AbbVie's largest in recent years, potentially expanding its portfolio in the immunology sector.